These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28549056)

  • 1. Resistance to first-line antiretroviral therapy.
    Cámara-Reyes R; Arce-Huamani MÁ; Franco-Soto ML; Díaz-Monge JC
    Medwave; 2017 May; 17(4):e6955. PubMed ID: 28549056
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital.
    Beldjebel I; Sokolova J; Krcmery V
    J Antimicrob Chemother; 2011 Apr; 66(4):956-7; author reply 957-8. PubMed ID: 21393221
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiretroviral therapy in HIV-infected children.
    Fan C; Zhang F; Chen C
    Minerva Pediatr; 2019 Oct; 71(5):455-460. PubMed ID: 27652902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV and drug resistance - interpretation and therapeutic progress.
    Gürtler L
    Intervirology; 2012; 55(2):77-8. PubMed ID: 22286873
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretroviral therapy for HIV: drug resistance and sequencing.
    Burkle WS
    J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862
    [No Abstract]   [Full Text] [Related]  

  • 6. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.
    Bannister WP; Cozzi-Lepri A; Kjær J; Clotet B; Lazzarin A; Viard JP; Kronborg G; Duiculescu D; Beniowski M; Machala L; Phillips A;
    J Antimicrob Chemother; 2011 Apr; 66(4):901-11. PubMed ID: 21393179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management of HIV-1 resistance.
    Paredes R; Clotet B
    Antiviral Res; 2010 Jan; 85(1):245-65. PubMed ID: 19808056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.
    Onoya D; Nattey C; Budgell E; van den Berg L; Maskew M; Evans D; Hirasen K; Long LC; Fox MP
    AIDS Patient Care STDS; 2017 May; 31(5):205-212. PubMed ID: 28445088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is laboratory monitoring of ART essential worldwide?
    Sutcliffe CG
    Lancet Infect Dis; 2011 Nov; 11(11):803-4. PubMed ID: 21831715
    [No Abstract]   [Full Text] [Related]  

  • 13. Do resistance patterns vary between different FTC containing drug regimens?
    Chacko L; Chamberlain F; Mandalia S; Nelson M
    J Infect; 2014 May; 68(5):503-5. PubMed ID: 24513393
    [No Abstract]   [Full Text] [Related]  

  • 14. Running with scissors: using antiretroviral therapy without monitoring viral load.
    Smith DM; Schooley RT
    Clin Infect Dis; 2008 May; 46(10):1598-600. PubMed ID: 18419496
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral therapy and resistance to antiretroviral drugs.
    Lange JM; van Leeuwen R
    Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A problem of the HIV drug resistance].
    Nosik MN
    Vopr Virusol; 2014; 59(4):5-9. PubMed ID: 25549461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa.
    Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; Rinke de Wit TF;
    J Infect Dis; 2012 Jun; 205(11):1739-44. PubMed ID: 22448003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.